Compare WDFC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | DNLI |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 1995 | 2017 |
| Metric | WDFC | DNLI |
|---|---|---|
| Price | $201.98 | $20.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $270.00 | $34.33 |
| AVG Volume (30 Days) | 108.8K | ★ 1.6M |
| Earning Date | 04-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 30.92 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $488,109,000.00 | N/A |
| Revenue This Year | $8.23 | N/A |
| Revenue Next Year | $5.85 | $408.85 |
| P/E Ratio | $71.42 | ★ N/A |
| Revenue Growth | ★ 19.49 | N/A |
| 52 Week Low | $175.38 | $12.58 |
| 52 Week High | $253.24 | $23.77 |
| Indicator | WDFC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 53.72 |
| Support Level | $199.17 | $18.27 |
| Resistance Level | $212.22 | $20.40 |
| Average True Range (ATR) | 5.95 | 0.92 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 49.29 | 71.47 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.